Sociedad Americana de Hirudoterapia

The direct thrombin inhibitor hirudin

Research article published in Thrombosis and haemostasis (2008)

Última actualización: March 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Desarrollo de fármacosEnsayos clínicosGreinacher A, Warkentin T · Thrombosis and haemostasis, 2008

Abstract

This review discusses the pharmacology and clinical applications of hirudin, a bivalent direct thrombin inhibitor (DTI). Besides the current major indication for hirudin--anticoagulation of patients with heparin-induced thrombocytopenia (HIT)--the experience with hirudin in other indications, especially acute coronary syndromes, are briefly presented. Hirudins have been formally studied prior to their regulatory approval; however, important information on their side effects and relevant preventative measures only became available later. Therefore, current recommendations and dosing schedules for hirudin differ considerably from the information given in the package inserts. Drawbacks of hirudin and important precautions for avoiding potential adverse effects are discussed in detail in the third part of this review.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAcute Coronary SyndromeAngioplasty, Balloon, CoronaryAnimalsAnticoagulantsBlood CoagulationBlood Coagulation TestsCardiopulmonary BypassDrug MonitoringFibrinolytic AgentsHemorrhageHemostasis, SurgicalHeparin

Resumen

This review discusses the pharmacology and clinical applications of hirudin, a bivalent direct thrombin inhibitor (DTI). Besides the current major indication for hirudin--anticoagulation of patients with heparin-induced thrombocytopenia (HIT)--the experience with hirudin in other indications, especially acute coronary syndromes, are briefly pres...

Por qué esto importa para la hirudoterapia

Relevant to the development and clinical application of leech-derived pharmaceutical compounds.

Citación

The direct thrombin inhibitor hirudin.

Greinacher A, Warkentin T · Thrombosis and haemostasis, 2008

Contexto clínico relacionado

Añadido a la biblioteca ASH: March 18, 2026 · Última actualización del sitio: March 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.

The direct thrombin inhibitor hirudin | ASH